ABUS vs MAS · P/E 5.4, rev $6.2M vs P/E 18, rev $7.83B
Arbutus Biopharma Corp (ABUS) versus Masco Corporation (MAS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Masco Corporation (MAS) is a building products & equipment company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MAS revenue for 2024-12-31 was $7.83B. Net income was $874.0M. Revenue was down 1.7% from 2023-12-31 to 2024-12-31. MAS currently screens at market cap $14.00B and trailing P/E 18.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MAS currently screens at market cap $14.00B and trailing P/E 18.1.
Not investment advice. Open the ABUS and MAS stock pages for the full models.
Not investment advice.